Biotech Valuation Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Valuation

CRSP 56.68

-2.4%

Dec 12 9:30 AM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Biomaven who started this subject	12/2/2003 4:03:21 PM
From: Ian@SI	of 52153

Oops, and it had been doing so well today... Sepracor Discontinues Tecastemizole Program 16:00 EST Tuesday, December 02, 2003 MARLBOROUGH, Mass., Dec. 2 /PRNewswire-FirstCall/ -- Sepracor Inc. (Nasdaq: SEPR) today announced that it has discontinued clinical development of SOLTARA(TM) brand tecastemizole for the treatment of allergic rhinitis. The U.S. Food and Drug Administration (FDA) issued a "not approvable" letter in March 2002 for Sepracor's New Drug Application (NDA) for SOLTARA for the treatment of allergic rhinitis. A "not approvable" letter is issued if the FDA believes that the application contains insufficient information for an approval action at that time [snip]

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next